A cholinephosphotransferase activity catalyzes the final step in the de novo synthesis of phosphatidylcholine via the transfer of a phosphocholine moiety from CDP choline to diacylglycerol. Ethanolaminephosphotransferase activity catalyzes a similar reaction substituting CDP ethanolamine as the phosphobase donor. We report the identification and cloning of a human cDNA (human cholinephosphotransferase (hCPT1)) that codes for a cholinephosphotransferase-specific enzyme. This was demonstrated using in vitro enzyme assays and in vivo measurement of the reconstitution of the phosphatidylcholine and phosphatidylethanolamine biosynthetic pathways in yeast cells devoid of their own endogenous cholinephosphotransferase and ethanolaminephosphotransferase activities. This contrasted with our previously cloned human choline/ethanolaminephosphotransferase cDNA that was demonstrated to code for a dual specificity choline/ethanolaminephosphotransferase. The hCPT1 and human choline/ethanolaminephosphotransferase (hCEPT1) predicted amino acid sequences possessed 60% overall identity and had only one variation in the amino acid residues within the CDP-alcohol phosphotransferase catalytic motif. In vitro assessment of hCPT1 and hCEPT1 derived cholinephosphotransferase activities also revealed differences in diradylglycerol specificities including their capacity to synthesize platelet-activating factor and platelet-activating factor precursor. Expression of the hCPT1 mRNA varied greater than 100-fold between tissues and was most abundant in testis followed by colon, small intestine, heart, prostate, and spleen. This was in marked contrast to the hCEPT1 mRNA, which has been found in similar abundance in all tissues tested to date. Both the hCPT1 and hCEPT1 enzymes were able to reconstitute the synthesis of PC in yeast to levels provided by the endogenous yeast cholinephosphotransferase; however, only hCEPT1-derived activity was able to complement the yeast CPT1 gene in its interaction with SEC14 and affect cell growth.
A cholinephosphotransferase activity catalyzes the final step in the de novo synthesis of phosphatidylcholine via the transfer of a phosphocholine moiety from CDP choline to diacylglycerol. Ethanolaminephosphotransferase activity catalyzes a similar reaction substituting CDP ethanolamine as the phosphobase donor. We report the identification and cloning of a human cDNA (human cholinephosphotransferase (hCPT1)) that codes for a cholinephosphotransferase-specific enzyme. This was demonstrated using in vitro enzyme assays and in vivo measurement of the reconstitution of the phosphatidylcholine and phosphatidylethanolamine biosynthetic pathways in yeast cells devoid of their own endogenous cholinephosphotransferase and ethanolaminephosphotransferase activities. This contrasted with our previously cloned human choline/ethanolaminephosphotransferase cDNA that was demonstrated to code for a dual specificity choline/ethanolaminephosphotransferase. The hCPT1 and human choline/ethanolaminephosphotransferase (hCEPT1) predicted amino acid sequences possessed 60% overall identity and had only one variation in the amino acid residues within the CDP-alcohol phosphotransferase catalytic motif. In vitro assessment of hCPT1 and hCEPT1 derived cholinephosphotransferase activities also revealed differences in diradylglycerol specificities including their capacity to synthesize platelet-activating factor and platelet-activating factor precursor. Expression of the hCPT1 mRNA varied greater than 100-fold between tissues and was most abundant in testis followed by colon, small intestine, heart, prostate, and spleen. This was in marked contrast to the hCEPT1 mRNA, which has been found in similar abundance in all tissues tested to date. Both the hCPT1 and hCEPT1 enzymes were able to reconstitute the synthesis of PC in yeast to levels provided by the endogenous yeast cholinephosphotransferase; however, only hCEPT1-derived activity was able to complement the yeast CPT1 gene in its interaction with SEC14 and affect cell growth.
Phosphatidylcholine (PC) 1 and phosphatidylethanolamine (PE) are the two most abundant phospholipids found in eukaryotic cells, generally comprising 50 and 25% of cellular phospholipid mass, respectively (1) . PC synthesis via the CDP choline pathway is responsible for essentially all de novo PC biosynthetic activity in all eukaryotic cell types thus far examined except (i) the liver where the methylation of phosphatidylethanolamine is predicted to contribute to 30% of net synthesis (2, 3) and (ii) yeast where the supply of exogenous choline dictates the relative contribution of the two PC biosynthetic pathways (4, 5) . PE can also be synthesized by alternate routes with the CDP ethanolamine pathway supplemented by the decarboxylation of phosphatidylserine to PE, with the relative contribution of each route dependent on cell type (6 -9) . The final step in the CDP alcohol pathways for the synthesis of PC and PE is catalyzed by cholinephosphotransferase and ethanolaminephosphotransferase enzyme activities, respectively. Cholinephosphotransferase catalyzes the transfer of phosphocholine from CDP choline to diacylglycerol (DAG) with the release of CMP and the formation of PC (10 -13) , whereas the ethanolaminephosphotransferase reaction catalyzes a similar transfer substituting CDP ethanolamine as the phosphobase donor resulting in the formation of PE (14 -16) . A cholinephosphotransferase has also been implicated in de novo synthesis of platelet-activating factor (PAF) (17, 18) . This putative PAF-specific cholinephosphotransferase was identified based on DTT susceptibility of cholinephosphotransferase activities measured in microsomal membranes, with PAF-specific activity being DTT resistant and PC-specific activity being DTT sensitive (18) .
The relative contribution of the CDP choline versus PE methylation pathways for the synthesis of PC have been implicated in regulating cell growth in the mammalian liver. PC synthesis through the CDP choline pathway favored proliferation, whereas PC synthesized by PE methylation inhibited cell growth and was negatively associated with the induction of liver tumor formation (19 -21) . PC molecules synthesized by these two pathways have different fatty acyl chain compositions and this has been postulated to be the major contributor to the observed effects on cell growth (3). The diacylglycerol specificity of cholinephosphotransferase regulates the fatty acyl composition of de novo PC synthesized through the CDP choline pathway and thus would be predicted to participate in the regulation of PC pathway-dependent liver tumor development. We recently cloned and characterized a human dual specificity choline/ethanolaminephosphotransferase (hCEPT1) capable of using both CDP choline and CDP ethanolamine as substrates in vitro (22) . Metabolic labeling experiments demonstrated this enzyme was able to reconstitute the synthesis of both PC and PE when expressed in a yeast strain in which the endogenous cholinephosphotransferase and ethanolaminephosphotransferase genes were inactivated. In the work presented here we de novo cloned two cDNAs, each coding for a splice variant of a human cholinephosphotransferase (hCPT1). The cDNA product was expressed for characterization in vitro and in vivo and was found to code for a cholinephosphotransferase-specific enzyme. Isolation of a Full-length hCPT1 cDNA-An analysis of the expressed sequence tags data bases (23) for clones with significant similarity to the active site of Saccharomyces cerevisiae cholinephosphotransferase (Cpt1p) resulted in the identification of two groups of mammalian cDNAs. Each group likely represented an isoform of mammalian cholinephosphotransferase. Alignment of the sequences within these groups revealed there were no full-length cDNAs represented for one of these groups. To obtain a full-length cDNA the longest expressed sequence tag clone (expressed sequence tag clone 67440) was obtained from the IMAGE consortium and sequenced in its entirety on both strands utilizing a combination of manual dideoxy (24) and automated techniques (Li-cor apparatus, National Research Council of Canada/ Dalhousie University Joint Laboratory). The 5Ј-end of the cDNA was successfully extended through two successive rapid amplification of cDNA ends (RACE) protocols (25) from human GT11 cDNA libraries. However, the 5Ј-end of the cDNA did not code for an obvious initiator Met residue. A full-length cDNA was isolated using the Genetrapper method (Life Technologies, Inc.) (26) by biotinylating an oligonucleotide corresponding to the most 5Ј-RACE extended sequence, 5Ј-TATCG-GCGGGTGGAGCACCGCTACAGC-3Ј, using terminal deoxynucleotide transferase and hybridizing the oligonuceltoide in solution to a singlestranded human brain cDNA library that had been generated by digestion of the library with Gene II protein and exonuclease III. Avidin bound to magnetic beads was used to selectively precipitate the biotinylated probe/hybridized cDNA complex to enrich the library for cDNAs complementary to the hCPT1-specific oligonucleotide. The singlestranded cDNAs were extended using Klenow, Escherichia coli were transformed, and colonies were screened for positive clones by hybridization versus an end-labeled hCPT1-specific antisense oligo 5Ј-CCAGT-CAGGATAAGTTCCTAAGCGA-3Ј. Separately, cDNA libraries for adult human eye tissues were constructed in the pCMVSPORT6 vector (Life Technologies, Inc.). Clones were picked for sequencing at the National Institutes of Health Intramural Sequencing Center (NISC). Novel, potential full-length clones were identified from 5Ј sequencing analyzed using BLAST at NCBI.
EXPERIMENTAL PROCEDURES

Materials-[␣-
Northern Blot Analysis-Random primed 32 P-labeled probes were synthesized versus either the entire 1.2-kb coding region of hCPT1 or a 2.0-kb region of human ␤-actin cDNA. Multiple human tissue Northern blots (CLONTECH) were hybridized at 68°C in ExpressHyb solution (27) for 1 h and washed as per the manufacturer's instructions. Blots were exposed to x-ray film for 1-3 days.
Protein Expression-The coding sequence for hCPT1 was amplified by PCR and subcloned into pET23a (Novagen) resulting in the addition of the coding sequence for a T7 epitope tag to the 5Ј-end of the open reading frame of hCPT1. The PCR-amplified fragment was sequenced in its entirety to ensure polymerase fidelity. The T7-tagged hCPT1 insert was then subcloned into p416GPD (28) for constitutive expression of hCPT1-encoded protein in S. cerevisiae. The HJ091 strain of S. cerevisiae is devoid of endogenous cholinephosphotransferase and ethanolaminephosphotransferase activities because of inactivated alleles at the loci coding for these activities (cpt1::LEU2 ept1 Ϫ ) (29, 30). Western Blot Analysis-Membranes were prepared from HJ091 S. cerevisiae cells (cpt1::LEU2 ept1 Ϫ ) grown to mid-log phase in appropriate medium to ensure plasmid maintenance (30, 31) . Proteins were incubated with SDS-polyacrylamide gel electrophoresis sample buffer at 37°C for 30 min, separated on a 12% SDS-polyacrylamide gel electrophoresis gel, and transferred to polyvinylidene difluoride membranes (32) . Blots were probed with a T7 epitope tag-specific monoclonal antibody (1:5000, Novagen) coupled to horseradish peroxidase for subsequent detection using the ECL (Amersham Pharmacia Biotech) system.
Enzyme Assays-Several assays for the measurement of cholinephosphotransferase and ethanolaminephosphotransferase activities were used in this study. Method one was routinely used unless otherwise indicated. This assay delivers lipids as an emulsion, whereby diradylglycerols or ceramides were dried under nitrogen gas and resuspended in 0.015% (w/v) Tween 20 by sonication. Unless otherwise indicated, assay buffer contained 100 mM Tris-HCl (pH 8.0), 20 mM MgCl 2 , 1 mM EDTA, 1 mM diradylglycerol or ceramide (final Tween 20 concentration of 0.004%, w/v), and 10 -25 g of microsomal protein. Components were incubated at room temperature for 5 min to allow for the lipids to be incorporated into the microsomal membrane and this was followed by the addition of CDP choline or CDP ethanolamine (0.4 mM, 2000 dpm/ nmol). Assays were incubated at 37°C for 15 min (33) . The second method used also delivered lipids in a lipid emulsion of either 0.1% Tween 20 or 0.1% deoxycholate (w/v) as the final detergent concentration (modified from Sleight and Kent (34)), but otherwise assay conditions were identical to method one. Method three used a PC liposome to deliver diacylglycerol to the membranes and was performed as described (35) . The final two methods used excess detergent to form mixed micelles using either Triton X-100 or sodium cholate. The Triton X-100 assay was performed as described (36) . The sodium cholate assay was modifed from the assay described by Bru et al. (37) and was performed in 50 mM Tris-HCl (pH 8.0), 20 mM MgCl 2 , 20% glycerol, and 10 mol % DAG and 10 mol % PC in 1% sodium cholate using 10 -25 g of membrane protein as the enzyme source. The assay mixture was incubated at 25°C for 5 min to allow for mixed micelle formation and then initiated by the addition of CDP choline or CDP ethanolamine (0.4 mM, 2000 dpm/nmol) and incubated at 25°C for 20 min.
The PC liposome assay was terminated as described (35) . Each of the other assays was terminated by the addition of 3 ml of CHCl 3 /CH 3 OH (2/1, v/v) and 1.5 ml of 0.9% (w/v) KCl to each 0.1-ml assay (38) . Tubes were vortexed, and phase separation was facilitated by centrifugation at 2000 ϫ g for 10 min. The aqueous phase was aspirated and the organic phase was washed twice with 1.5 ml of 40% CH 3 OH/H 2 O (v/v). An aliquot of the organic phase was dried in a scintillation vial, and radioactivity was determined. Samples were routinely analyzed by thin layer chromatography on silica gel plates in a solvent system of CHCl 3 / CH 3 OH/NH 4 OH/H 2 O (70/30/4/2, v/v) to confirm products. Some assays resulted in low levels of activity in the absence of added exogenous diradylglycerol because of utilization of endogenous diacylglycerols present in the membrane preparations. These values were subtracted from standard enzyme assays to obtain specific enzyme activity values for each diradylglycerol species.
Metabolic Labeling-S. cerevisiae HJ091 cells (cpt1::LEU2 ept1 Ϫ ) transformed with either hCPT1 or hCEPT1 in the constitutive expression vector p416GPD, or empty p416GPD vector, were grown to mid-log phase in synthetic dextrose medium containing appropriate nutritional supplements to ensure plasmid maintenance (31 (22) . The reduced nitrogen-containing medium was required for the efficient uptake of ethanolamine. Subsequent to incubation with radiolabel, cells were concentrated by centrifugation, washed twice with water, and resuspended in 1 ml of CHCl 3 /CH 3 OH (1/1, v/v). Cells were disrupted for 1 min at 4°C using a BioSpec Multi Bead Beater containing 0.5 g of 0.5-mm acid-washed glass beads. The beads were washed with 1.5 ml of CHCl 3 /CH 3 OH (2/1, v/v). To facilitate phase separation 1.5 ml of water and 0.5 ml of CHCl 3 were added. Phospholipids in the organic phase were routinely analyzed by thin layer chromatography on Whatman silica gel 60A plates using the solvent system CHCl 3 /CH 3 OH/H 2 0/CH 3 COOH (70/30/4/2, v/v) for subsequent radioactivity determination by scintillation counting.
Yeast Phenotype Complementation-S. cerevisiae strain CTY434 (a ura3-52 ade2-101 leu2-3, 112 his4 -519 s14 ts cpt1::LEU2, a kind gift from Dr.Vytas Bankaitis) transformed with expression plasmids containing hCPT1, hCEPT1, yeast CPT1, or vector controls were grown overnight in synthetic dextrose medium under selection for plasmid maintenance at 25°C (31) . Cell density was estimated by monitoring A 600 of a 1:10 dilution into water. Identical cell numbers were serialdiluted 1:10 into water, and 1 l of each dilution was spotted onto synthetic minimal medium agar plates supplemented as required for cell growth and plasmid maintenance. Plates were incubated for 4 days at 25 or 37°C.
Protein and Lipid Determinations-Protein was determined by the method of Lowry et al. (39) using bovine serum albumin as the standard. Diradylglycerols not available commercially were prepared from PC by digestion with Bacillus cereus phospholipase C, and the yield was estimated using the method of Stern and Shapiro (40) . Phospholipid phosphorus was determined by the method of Ames and Dubin (41) .
RESULTS
Isolation of a Full-length Human Cholinephosphotransferase 1 cDNA-Previous structure/function analysis of the integral membrane-bound yeast cholinephosphotransferase (CPT1) and choline/ethanolaminephosphotransferase (EPT1) enzymes resulted in several predictions (11, 29) . The first three membrane-spanning helices are the maximum region required for DAG binding, and the first cytoplasmic loop is required for CDP alcohol binding. Within the CDP alcohol binding region of CPT1 and EPT1, and also present in several other phospholipid synthesizing enzymes that catalyze the displacement of a CDP alcohol by a second alcohol for the formation of a phosphoester bond, is a CDP-alcohol phosphotransferase motif (Asp-Gly-X 2 -Ala-Arg-X 8 -Gly-X 3 -Asp-X 3 -Asp). Site-directed mutagenesis analysis studies predict this motif performs catalysis by employing the final two Asp residues in a general base reaction that does not proceed through an enzyme-bound intermediate (30) . A search of the expressed sequence tag data base (23) for cDNAs with similarity to the yeast Cpt1p CDP-alcohol phosphotransferase motif revealed two classes of mammalian cDNAs. An alignment of all of the members of one class revealed that one of the human cDNAs was full-length (hCEPT1) and this cDNA was previously expressed and found to be capable of (i) synthesizing PC and PE in vitro and (ii) metabolically reconstituting both the CDP choline and CDP ethanolamine pathways in vivo in a yeast strain where the endogenous cholinephosphotransferase and ethanolaminephosphotransferase genes had been inactivated (22) . Alignment of the members of the second class of mammalian cDNAs with similarity to the yeast Cpt1p CDP-alcohol phosphotransferase motif revealed that none of the cDNAs were full-length. In the present study, we extended the longest of these partial cDNAs by an additional 322 base pairs by two successive 5Ј-RACE protocols, and a subsequent screen of a human brain cDNA library with an oligonucleotide derived from the most 5Ј-end of the furthest RACE extension resulted in our isolation of five cDNAs of sufficient length to code for a full-length cholinephosphotransferase protein. Each of these cDNAs was sequenced in its entirety and found to contain an insert of 1505-1532 base pairs (plus poly(A) tails) indicating the cDNAs extended through to the 3Ј-end of the mRNA transcript. Three of the cDNAs coded for a protein of 407 amino acids (hCPT1, GenBank TM accession number AF195623). cDNA clones for hCPT1 were also isolated as part of NEIBANK and expressed sequence tag survey of human eye tissues. Of ϳ2000 expressed sequence tags from the adult human iris, two cDNAs for hCPT1 were obtained including one full-length clone designated bx02f09. One additional clone was identified of a total of over 8000 clones from adult human retinal pigment epithelium/choroid. The full-length hCPT1 amino acid sequence is 60% identical to hCEPT1 (Fig. 1A) , and hydropathy plots predict proteins with very similar secondary structures (Fig. 1B ). An inspection of the hCPT1 amino acid sequence revealed the presence of the CDPalcohol phosphotransferase motif at amino acids 114 -136 and an estimated seven membrane-spanning helices.
Two of the cDNAs isolated from the human brain library colony screen contained an identical cDNA to hCPT1 except for an insert of 27 base pairs (corresponding to predicted amino acid 217) that resulted in a termination codon coded for at amino acid 219 (hCPT1␤, GenBank TM accession number AF195624). This would produce a hCPT1␤ protein consisting of the CDP alcohol binding motif and the first two predicted membrane-spanning helices. Based on previous analysis of the highly similar yeast CPT1 gene product (11, 29, 30 ) the hCPT1␤ protein would consist of only the catalytic portion of the enzyme.
Genomic Organization of Human Cholinephosphotransferase 1-Similarity searches of public data bases were used for determination of the genomic locations of hCEPT1 and hCPT1. The hCEPT1 gene has been mapped to chromosome 1 between microsatellite markers D1S2865 and D1S418 by several groups but its precise DNA sequence is not known (42) . The hCPT1 gene was positioned to chromosome 12q between microsatellite markers D12S346 and D12S78, and a BAC clone from the human genome sequencing project contained the entire hCPT1 gene sequence and flanking DNA (GenBank TM accession number AC010205). The hCPT1 gene is 32 kb in length and is comprised of 9 exons (Fig. 2 ). An analysis of the hCPT1 gene indicated that the extra DNA sequence found in the hCPT1␤ cDNAs was contained within the hCPT1 gene (exon 4a) implying the hCPT1␤ cDNA isolated is a true splice variant. To further validate if hCPT1␤ represents a hCPT1 splice variant, several different human cDNA libraries were subjected to PCR analysis using primers that span the predicted exon insertion site of hCPT1␤ (Fig. 2) . Each of the libraries possessed cDNAs coding for hCPT1 and the hCPT1␤ splice variant, except for those derived from the iris and retinal pigment epithelium, which contained only the hCPT1 cDNA. We have been successful in expressing hCPT1-derived protein for subsequent enzymatic and metabolic assessments and are currently working to establish if hCPT1␤ codes for an active enzyme.
hCPT1 mRNA Expression-The relative distribution of hCPT1 mRNA in human tissues was assessed by Northern blot (Fig. 3) . Because of the small difference in cDNA sequence between hCPT1 and hCPT1␤ (27-base pair insertion) the blot is likely a composite of the expression of the two splice variants. Only one transcript size was detected at 1.6 kb. Transcript levels ranged greater than 100-fold between various tissues. The mRNA for hCPT1 was most abundant in testis followed by slightly less transcript in the colon, small intestine, heart, prostate, spleen, and liver. The transcript was also detected in the kidney, skeletal muscle, pancreas, leukocytes, ovary, and thymus. There was very low expression in the brain, placenta, and lung. This is in marked contrast to the transcript levels of hCEPT1, which was found in similar amounts in each of the above tissues (22) .
Expression and Enzymatic Characterization of hCPT1 and hCEPT1-To enzymatically assess hCPT1 substrate specificities, the hCPT1 coding region was inserted in frame with a T7 epitope tag for expression in the S. cerevisiae strain HJ091 (cpt1::LEU2 ept1 Ϫ ). This yeast is devoid of its endogenous cholinephosphotransferase and ethanolaminephosphotransferase activities because of inactivation of the genomic loci coding for these activities (29, 30) . This ensured any enzyme activity observed was derived from the transformed hCPT1 or hCEPT1 coding sequences. The hCPT1 protein was successfully expressed in S. cerevisiae as a full-length protein as determined by Western blot analysis, albeit at levels significantly lower than that for hCEPT1 expressed from the identical vector (Fig. 4) . There are several commonly used assays for measurement of mammalian cholinephosphotransferase and ethanolaminephosphotransferase activities (33-37). The assays are very similar except for (i) the nature in which the DAG substrate is solubilized for subsequent delivery in the assay mixture and (ii) the use of Mg 2ϩ or Mn 2ϩ as the essential cation. We tested the delivery of DAG in Tween 20 emulsions (33), a deoxycholate emulsion (34), complexed with PC in liposomes (35), in Triton X-100-mixed micelles (36) or in sodium cholatemixed micelles (37), using either Mg 2ϩ or Mn 2ϩ as an essential cation donor.
We first determined the best method for delivery of DAG to hCPT1 (Table I ). The highest enzyme activity was observed using DAG delivery in either a very small amount of Tween 20 (0.004%) or in PC liposomes. We were unable to detect ethanolaminephosphotransferase activity, with any of the diradylglycerol species tested, under each of the assay conditions employed. We chose to characterize hCPT1 further using the Tween 20 assay conditions as (i) this was the assay used in our initial characterization of hCEPT1 activity (22) and (ii) this assay was also used to demonstrate the existence of a putative microsomal PAF-specific cholinephosphotransferase activity (17, 18) . We also determined the Mg 2ϩ and Mn 2ϩ requirement for hCPT1-derived cholinephosphotransferase activity and an essential requirement for either cation was observed (Fig. 5) ; however, Mg 2ϩ activated enzyme activity to levels 10-fold higher than Mn 2ϩ . The specificity of the DAG donor was also determined in the presence of either Mg 2ϩ or Mn 2ϩ (Table II) . In general, Mg 2ϩ -derived activities were higher than those obtained using Mn 2ϩ as the essential cation for most substrates. The DAG specificity of the Mg 2ϩ -derived activities was di18 PAF in vitro and enzyme activities of 24.9 nmol min Ϫ1 mg Ϫ1 for the synthesis of PAF and 5.5 nmol min Ϫ1 mg Ϫ1 for the PAF precursor were observed.
A PAF-specific cholinephosphotransferase activity detected in crude subcellular extracts was previously differentiated from PC-specific activity based on DTT sensitivity (17, 18) . The PAF-specific activity was slightly stimulated by DTT, whereas the PC-specific activity was greatly inhibited by DTT. We repeated these experiments using the cloned hCPT1 and hCEPT1 as specific enzyme sources. Low concentrations of DTT moderately increased the activity of hCPT1 for the synthesis of PC and surprisingly allowed hCPT1 to now synthesize PAF (Fig. 6A) . Hence, hCPT1 does have the capacity to synthesize PAF in vitro, and this ability is dependent upon the inclusion of DTT in the assay mixture. Activities for both substrates peaked at 0.1-1.0 mM DTT with a slight decrease in activity at 5 mM DTT compared with peak values. The hCEPT1-derived cholinephosphotransferase activity was also capable of synthesizing both PAF and PC; however, DTT did not alter the activity of hCEPT1 toward either substrate (Fig. 6B) .
In Vivo Assessment of hCPT1 and hCEPT1 CDP Alcohol Specificity-Although we determined that hCPT1 could use only CDP choline, and not CDP ethanolamine, as a substrate under a variety of in vitro assay conditions, we sought to confirm this observation in vivo. We expressed both hCPT1 and hCEPT1 in a yeast strain devoid of its endogenous cholinephosphotransferase and ethanolaminephosphotransferase activities because of genomic inactivation of the alleles coding for the yeast enzymes (HJ091, cpt1::LEU2 ept1). We then tested the ability of hCPT1 and hCEPT1 to reconstitute the CDP choline pathway for the synthesis of PC and the CDP ethanolamine pathway for the synthesis of PE, by the addition of radiolabeled choline or ethanolamine, respectively. Expression of hCPT1 resulted in the ability to incorporate radiolabeled choline into PC, but we were unable to detect any radiolabel in the lipid fraction of the ethanolamine-labeled cells (Fig. 7) . Expression of hCEPT1 resulted in the reconstitution of both the PC and PE biosynthetic pathways. Hence, the in vivo results for hCPT1 FIG. 2 . Structure of the hCPT1 gene and analysis of hCPT1 splice variants. A, the predicted intron/exon splice junctions of the hCPT1 gene. B, PCR analysis of cDNA libraries generated from the indicated human tissues using primers that span the predicted hCPT1␤ exon. The hCPT1-specific primers used were 5Ј-GAACAGGAAAATAT-TACTCCACC-3Ј and 5Ј-GCTTTAGTGATTGTCTTTGTGTTG-3Ј. Amplification of the hCPT1 cDNA would result in a DNA fragment of 134 base pairs whereas the hCPT1␤ cDNA would produce a 161-base pair fragment. C, PCR analysis of cDNA libraries generated from human iris and retinal pigment epithelium using primers that span the predicted hCPT1␤ exon. The hCPT1-specific primers used were 5Ј-GTTGAGATT-TGGAAAAGTGGATGTAAC-3Ј and 5Ј-GGATCCATTCTTGCCAACAC-CACCATG-3Ј. Amplification of the hCPT1 cDNA would result in a DNA fragment of 222 base pairs, whereas the hCPT1␤ cDNA would produce a 249-base pair fragment. D, the hCPT1 amino acids encoded by each hCPT1 exon. and hCEPT1 correlated with our in vitro assessment of their substrate specificities. It should be pointed out that although the expression of hCEPT1 was ϳ10-fold higher than hCPT1 in yeast as determined by Western blot and 20-fold higher as assessed by in vitro enzyme activities, both hCPT1 and hCEPT1 reconstituted the PC biosynthetic pathway to similar levels. This rate of PC synthesis was analogous to that observed for the endogenous yeast cholinephosphotransferase enzyme (11, 30) . The lack of correlation of expression levels with the rate of PC synthesis is consistent with previous observations that the cholinephosphotransferase step is normally not rate-limiting for the synthesis of PC. Indeed, either a 5-fold increase or 10-fold decrease in yeast CPT1 activity did not alter the in vivo rate of PC synthesis from labeled choline (11) .
Role of hCPT1 and hCEPT1 in Vesicle Trafficking-In yeast, the regulation of PC synthesis has been specifically implicated in SEC14-dependent vesicle trafficking from the Golgi apparatus (43) (44) (45) (46) . SEC14 codes for a PC/phosphatidylinositol transfer protein, which in vitro catalyzes transport of phospholipid monomers from one membrane bilayer to another (47) and in vivo is believed to act as a sensor of PC levels that in turn regulates lipid homeostasis for subsequent downstream regulation of Golgi-derived vesicle trafficking (48) . Inactivation of SEC14 function is lethal; however, a temperature-sensitive conditional allele of SEC14 (sec14 ts ) was used in a screen to isolate bypass mutations of the normally essential SEC14 function. This screen demonstrated that inactivating mutations in several structural genes relieved the cell of its essential requirement for SEC14 (44) . Three of these genes coded for each of the enzymes of the CDP choline pathway for PC biosynthesis. Inactivating mutations in genes of the CDP ethanolamine pathway for PE synthesis did not bypass the requirement for SEC14. Hence, the synthesis of PC by the CDP choline pathway specifically regulated SEC14-mediated Golgi-derived vesicle trafficking events. To preliminarily test if hCPT1 or hCEPT1 might be involved in the regulation of vesicle trafficking, these enzymes were expressed in a yeast strain containing FIG. 5 . Cation requirement of hCPT1. Enzyme activities were determined using the Tween 20 (0.004%) assay with di18:1 diacylglycerol as described under "Experimental Procedures" from microsomal membranes of yeast devoid of their endogenous cholinephosphotransferase activity (cpt1::LEU2 ept1 Ϫ ) but constitutively expressing hCPT1. Ϫ ), and radiolabeled choline or ethanolamine was added to exponential phase cells for 1 h as described under "Experimental Procedures." Lipids were extracted from the cells, and the amount of radiolabel incorporated into lipid was determined by scintillation counting.
both a sec14 ts temperature-sensitive allele and an inactivated yeast cholinephosphotransferase gene (cpt1::LEU2). The sec14 ts cpt1::LEU2 yeast can grow at the nonpermissive temperature for sec14 ts function because of the inactivated CPT1 allele (cpt1::LEU2). Because both hCPT1 and hCEPT1 could reconstitute PC synthesis in yeast lacking endogenous cholinephosphotransferase activity, we tested whether hCPT1 or hCEPT1 could also complement yeast CPT1 function with respect to SEC14-mediated Golgi vesicle transport. Either hCPT1, hCEPT1, or yeast CPT1 were expressed in the sec14 ts cpt1::LEU2 yeast strain, and the ability of the cells to grow at both the permissive (25°C) and nonpermissive (37°C) sec14 ts temperature was monitored. As expected, expression of the yeast CPT1 enzyme resulted in cells that were unable to grow at 37°C because of restoration of the sec14 ts phenotype (Fig. 8) . Expression of the hCEPT1 protein in sec14 ts cpt1::LEU2 yeast also resulted in cells unable to grow at 37°C indicating hCEPT1 activity can successfully complement the yeast CPT1-derived protein with respect to its interaction with SEC14-mediated vesicle transport events. Surprisingly, expression of hCPT1 in the same yeast did not affect growth at the nonpermissive temperature of 37°C. Hence, although expression of both hCEPT1 and hCPT1 both reconstituted PC synthesis to levels similar to those provided by the endogenous yeast CPT1 gene, hCEPT1, but not hCPT1, was able to affect SEC14-mediated cell growth.
DISCUSSION
The final steps in the Kennedy pathways for the synthesis of PC and PE are catalyzed by cholinephosphotransferase and ethanolaminephosphotransferase activities, respectively (10 -16). The hCPT1 cDNA described in this study codes for an enzyme that demonstrated cholinephosphotransferase activity in in vitro enzyme assays, and in yeast devoid of their endogenous cholinephosphotransferase activity, hCPT1 was able to reconstitute the PC biosynthetic pathway in vivo. The hCPT1 enzyme was unable to use CDP ethanolamine as a substrate in vitro and was unable to reconstitute the PE biosynthetic pathway in vivo. This is in contrast to our previously isolated human hCEPT1 cDNA, which encoded an activity capable of using both CDP choline and CDP ethanolamine as substrates in vitro and in vivo (22) . It has been presumed that Kennedy pathways for the synthesis of PC and PE are completely separate in mammalian cells (49, 50) ; however, the redundancy of cholinephosphotransferase activity in both the hCPT1 and hCEPT1 enzymes and the dual specificity of hCEPT for the synthesis of PC and PE imply that these two pathways may not be metabolically distinct. Indeed, the hCEPT1 mRNA distribution was similar in all tissues tested, whereas the hCPT1 mRNA varied greater than 100-fold between the same tissues, implying tissue-specific expression of hCPT1. Consistent with different functions for hCPT1 and hCEPT1 was the ability of hCEPT1, and not hCPT1, to complement the yeast CPT1 protein in mediating SEC14-dependent cell growth, even though both hCEPT1 and hCPT1 both reconstituted in vivo PC synthesis to levels similar to those provided by the yeast CPT1 gene product. In plants there is evidence that PC and PE are synthesized by a dual specificity choline/ethanolaminephosphotransferase (51, 52) , and it will be interesting to determine if hCEPT1 can perform both functions in mammalian cells. A Chinese hamster ovary cell line had been produced by random mutagenesis with a specific defect in ethanolaminephosphotransferase activity (53) , and it would have been illuminating to express the hCPT1 and hCEPT1 products in this cell line; unfortunately, this cell line is no longer available.
Consistent with our hypothesis that hCPT1 and hCEPT1 functions may not be metabolically distinct was an examination of the expressed sequence tag data bases, which failed to uncover other mammalian cDNAs with similarity to hCPT1 or hCEPT1. This implies the two cDNAs isolated to date likely comprise the total complement of human cholinephosphotransferase-and ethanolaminephosphotransferase-encoded activities. This would be similar to the demonstrated gene complement in S. cerevisiae (CPT1 and EPT1) (29), and an examination of the completed C. elegans data base also revealed only two genes coding for enzymes with similarity to hCPT1 and hCEPT1 (54) . Inconsistent with the hypothesis that hCEPT1 may function in both the CDP choline and CDP ethanolamine pathways in mammalian cells is the report of an ethanolaminephosphotransferase-specific enzyme purified to near homogeneity from bovine liver (15) . It will be interesting to determine if the purified ethanolaminephosphotransferase is indeed coded for by the bovine CEPT1 gene, but confirmation awaits peptide sequencing of the purified protein.
A PAF-specific cholinephosphotransferase activity had been previously distinguished from the PC-specific cholinephosphotransferase enzyme based on DTT sensitivity (17, 18) . Microsomal membranes contained a PAF-specific cholinephosphotransferase activity that was moderately stimulated by DTT and a PC-specific cholinephosphotransferase activity that was inhibited by DTT. We found that the cloned hCPT1 and hCEPT1 were both able to synthesize PAF in vitro. The hCPT1 PAF-synthesizing activity was stimulated and dependent on DTT, whereas the hCEPT1 PAF synthesizing activity was unaffected by DTT. Neither hCPT1 nor hCEPT1 PC biosynthetic activity was inhibited by DTT. Hence, neither the hCPT1 nor the hCEPT1-encoded cholinephosphotransferase activities reflected those previously observed in mammalian microsomes for the synthesis of PAF and PC. As yeast do not contain ether linked lipids, the precise in vivo substrate specificity for the synthesis of ether-linked PC molecules by hCPT1 and hCEPT1 awaits the development of mammalian systems for subsequent analyses. However, we predict simple overexpression systems are unlikely to provide insight into hCPT1 and hCEPT1 substrate specificities as the cholinephosphotransferase step is not rate-limiting in the pathway, and thus more complicated knockout or antisense strategies will likely have to evolve; these are currently under development. FIG. 8 . Ability of hCPT1 and hCEPT1 to affect SEC14-dependent cell growth. S. cerevisiae cells containing a temperature-sensitive SEC14 allele (sec14 ts ) and an inactivated CPT1 gene (cpt1::LEU2) were transformed with plasmids for the constitutive expression of hCPT1, hCEPT1, yeast CPT1, and an empty vector control. Cells were grown overnight in liquid broth at 25°C, and identical numbers of cells were serial diluted 1:10 and spotted onto minimal medium plates containing the required nutrients for plasmid maintenance. Plates were incubated at 25 or 37°C for 4 days.
